{
  "source": "PA-Notification-Kevzara.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1223-9\nProgram Prior Authorization/Notification\nMedication Kevzara® (sarilumab) Injection\nP&T Approval Date 7/2017, 7/2018, 7/2019, 7/2020, 7/2021, 7/2022, 4/2023, 7/2023,\n8/2024\nEffective Date 11/1/2024\n1. Background:\nKevzara (sarilumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of\nadult patients with moderately to severely active rheumatoid arthritis who have had an\ninadequate response or intolerance to one or more disease-modifying antirheumatic\ndrugs (DMARDs).1 Examples of DMARDs commonly used in the treatment of rheumatoid\narthritis include methotrexate, leflunomide, and sulfasalazine.2,3 Kevzara is also indicated for\nthe treatment of adult patients with polymyalgia rheumatica (PMR) who have had an\ninadequate response to corticosteroids or who cannot tolerate corticosteroid taper and for the\ntreatment of patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic\narthritis (pJIA).\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Kevzara will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient has had an inadequate response or intolerance to one or more disease-\nmodifying anti-rheumatic drugs (DMARDs) (e.g., methotrexate, leflunomide,\nsulfasalazine)\n-AND-\n(3) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kevzara will be approved based on both of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with ",
    "h of the following criteria:\n© 2024 UnitedHealthcare Services, Inc.\n1\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\nB. Polymyalgia Rheumatica (PMR)\n1. Initial Authorization\na. Kevzara will be approved based on all of the following criteria:\n(1) Diagnosis of polymyalgia rheumatica (PMR)\n-AND-\n(2) Patient has had an inadequate response to corticosteroids or cannot tolerate\ncorticosteroid taper\n-AND-\n(3) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kevzara will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nC. Polyarticular Juvenile Idiopathic Arthritis (pJIA)\n1. Initial Authorization\na. Kevzara will be approved based on both of the following criteria:\n(1) Diagnosis of active polyarticular juvenile idiopathic arthritis\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (ab",
    "ritis\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Kevzara will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Kevzara therapy\n-AND-\n(2) Patient is not receiving Kevzara in combination with another targeted\nimmunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel\n(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq\n(upadacitinib), Simponi (golimumab), Xeljanz/Xeljanz XR (tofacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n4. References:\n1. Kevzara [package insert]. Bridgewater, NJ: Sanofi-Aventis.; June 2024.\n2. Pavy S. Constantin A, Pham T, et al. Methotrexate therapy for rheumatoid arthritis: clinical\npractice guidelines based on published evidence and expert opinions. Joint Bone Spine\n2006;73(4):388-95.\n© 2024 UnitedHealthcare Services, Inc.\n3\n3. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology\nGuideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol.\n2021;73(7):1108-1123. doi:10.1002/art.41752\nProgram Prior Authorization/Notification – Kevzara (sarilumab)\nChange Control",
    "logy\nGuideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol.\n2021;73(7):1108-1123. doi:10.1002/art.41752\nProgram Prior Authorization/Notification – Kevzara (sarilumab)\nChange Control\n7/2017 New program.\n7/2018 Annual review. Updated references.\n7/2019 Annual review. No changes to coverage criteria.\n7/2020 Annual review. Updated reauthorization issue duration.\n7/2021 Annual review. No changes to coverage criteria.\n7/2022 Annual review. Updated language of criterion to match with prescribing\ninformation without change in clinical intent. Added state mandate and\nupdated references.\n4/2023 Added coverage criteria for polymyalgia rheumatica. Updated Humira\nto adalimumab and added Rinvoq in drug examples. Updated\nbackground and references.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n8/2024 Added clinical coverage criteria for pJIA. Updated background and\nreference. Alphabetized targeted immunomodulator examples with no\nchange to intent.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}